Russell Schilder
Gynecologic Oncology Group
5
5
4
N/A
0
0
Research Impact
N/A
Research impact score
0
Total publications
0
Published trial results
0
Total citations
Drug Portfolio
+3 more interventions
Analytics
Trial Phases
Trial Status
Role Distribution
Activity Timeline
Clinical Trials (5)
Research Network
Collaboration Network
Research Areas & Affiliations
Therapeutic Areas
Affiliations
Similar Key Opinion Leaders
Discover other key opinion leaders with similar research profiles, therapeutic areas, and collaboration networks.
Lupe Salazar
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Shared therapeutic areas:
Worked with same sponsors:
Emese Zsiros
Roswell Park Cancer Institute
Shared therapeutic areas:
Worked with same sponsors:
Shannon N Westin
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Amir A Jazaeri
M.D. Anderson Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Aminah Jatoi, M.D.
Mayo Clinic
Shared therapeutic areas:
Worked with same sponsors:
Robert Kreitman, MD
National Cancer Institute (NCI)
Shared therapeutic areas:
Worked with same sponsors:
Ursula Matulonis, MD
Dana-Farber Cancer Institute
Shared therapeutic areas:
Vincent Chung
City of Hope Medical Center
Shared therapeutic areas:
Worked with same sponsors:
Brigitte E. Miller, MD
Wake Forest University Health Sciences
Shared therapeutic areas:
Worked with same sponsors:
Lee M. Krug, MD
Memorial Sloan Kettering Cancer Center
Shared therapeutic areas:
Worked with same sponsors:
Publications (0)
No publications found for this investigator.
Clinical Trials (5)
Showing 5 of 5 trials
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer
Erlotinib in Treating Patients With Persistent or Recurrent Cancer of the Cervix
Imatinib Mesylate in Treating Patients With Persistent or Recurrent Ovarian Epithelial or Primary Peritoneal Cancer
Irofulven in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cancer
A Phase II Evaluation of Dasatinib (Sprycel®, NSC #732517) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma
All 5 trials loaded